

Hans H Maurer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9373866/publications.pdf>

Version: 2024-02-01

322
papers

14,050
citations

17440

63
h-index

40979

93
g-index

343
all docs

343
docs citations

343
times ranked

7304
citing authors

#	ARTICLE	IF	CITATIONS
1	A proposed approach to confirm heroin administration – Regional differences in heroin purity is a major factor. <i>Regulatory Toxicology and Pharmacology</i> , 2022, 128, 105097.	2.7	0
2	Hyphenated high-resolution mass spectrometry – the “all-in-one” device in analytical toxicology?. <i>Analytical and Bioanalytical Chemistry</i> , 2021, 413, 2303-2309.	3.7	21
3	Toxicokinetic studies of the four new psychoactive substances 4-chloroethcathinone, N-ethylnorpentylone, N-ethylhexedrone, and 4-fluoro-alpha-pyrrolidinohexiophenone. <i>Forensic Toxicology</i> , 2020, 38, 59-69.	2.4	18
4	Pitfalls in drug testing by hyphenated low- and high-resolution mass spectrometry. <i>Drug Testing and Analysis</i> , 2020, 12, 172-179.	2.6	14
5	Is adipose tissue suitable for detection of (synthetic) cannabinoids? A comparative study analyzing antemortem and postmortem specimens following pulmonary administration of JWH-210, RCS-4, as well as Δ^9 -tetrahydrocannabinol to pigs. <i>Archives of Toxicology</i> , 2020, 94, 3421-3431.	4.2	5
6	Time- and temperature-dependent postmortem concentration changes of the (synthetic) cannabinoids JWH-210, RCS-4, as well as Δ^9 -tetrahydrocannabinol following pulmonary administration to pigs. <i>Archives of Toxicology</i> , 2020, 94, 1585-1599.	4.2	10
7	Development and application of a strategy for analyzing eight biomarkers in human urine to verify toxic mushroom or ricinus communis ingestions by means of hydrophilic interaction LC coupled to HRMS/MS. <i>Talanta</i> , 2020, 213, 120847.	5.5	15
8	<i>In vitro</i> glucuronidation of designer benzodiazepines by human UDP-glucuronyltransferases. <i>Drug Testing and Analysis</i> , 2019, 11, 45-50.	2.6	18
9	Blood plasma level determination using an automated LC-MS ⁿ screening system and electronically stored calibrations exemplified for 22 drugs and two active metabolites often requested in emergency toxicology. <i>Drug Testing and Analysis</i> , 2019, 11, 102-111.	2.6	11
10	Evaluation of novel organosilane modifications of paper spray mass spectrometry substrates for analyzing polar compounds. <i>Talanta</i> , 2019, 204, 677-684.	5.5	9
11	Distribution of the (synthetic) cannabinoids JWH-210, RCS-4, as well as Δ^9 -tetrahydrocannabinol following pulmonary administration to pigs. <i>Archives of Toxicology</i> , 2019, 93, 2211-2218.	4.2	16
12	Overview of Common Designer Drugs. , 2019, , 237-246.		3
13	Metabolic fate of the new synthetic cannabinoid 7- TM N-5F-A TM ADB in rat, human, and pooled human S9 studied by means of hyphenated high-resolution mass spectrometry. <i>Drug Testing and Analysis</i> , 2019, 11, 305-317.	2.6	23
14	Interactions of phenethylamine-derived psychoactive substances of the 2C-series with human monoamine oxidases. <i>Drug Testing and Analysis</i> , 2019, 11, 318-324.	2.6	13
15	Cytotoxicity of new psychoactive substances and other drugs of abuse studied in human HepG2 cells using an adopted high content screening assay. <i>Toxicology Letters</i> , 2019, 301, 79-89.	0.8	14
16	In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures. <i>Analytical and Bioanalytical Chemistry</i> , 2019, 411, 4751-4763.	3.7	34
17	Refined protocols of tamoxifen injection for inducible DNA recombination in mouse astroglia. <i>Scientific Reports</i> , 2018, 8, 5913.	3.3	98
18	Bioanalytical Methods for New Psychoactive Substances. <i>Handbook of Experimental Pharmacology</i> , 2018, 252, 413-439.	1.8	39

#	ARTICLE	IF	CITATIONS
19	Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. <i>Toxicology Letters</i> , 2018, 285, 1-8.	0.8	19
20	Different in vitro and in vivo tools for elucidating the human metabolism of alpha-cathinone-derived drugs of abuse. <i>Drug Testing and Analysis</i> , 2018, 10, 1119-1130.	2.6	23
21	Metabolism of the tryptamine-derived new psychoactive substances 5-MeO-2-Me-DALT, 5-MeO-2-Me-ALCHT, and 5-MeO-2-Me-DIPT and their detectability in urine studied by GC-MS, LC-MS ⁿ , and LC-HR-MS/MS. <i>Drug Testing and Analysis</i> , 2018, 10, 184-195.	2.5	25
22	The NTCP-inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 341-348.	4.7	66
23	LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening power with further MS techniques. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 897-912.	3.7	24
24	Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometry. <i>Talanta</i> , 2018, 176, 635-645.	5.5	28
25	A multi-analyte approach to help in assessing the severity of acute poisonings – Development and validation of a fast LC-MS/MS quantification approach for 45 drugs and their relevant metabolites with one-point calibration. <i>Drug Testing and Analysis</i> , 2018, 10, 164-176.	2.6	15
26	Power of Orbitrap-based LC-high resolution-MS/MS for comprehensive drug testing in urine with or without conjugate cleavage or using dried urine spots after on-spot cleavage in comparison to established LC-MS ⁿ or GC-MS procedures. <i>Drug Testing and Analysis</i> , 2018, 10, 158-163.	2.6	17
27	Relevance of published blood concentrations of new psychoactive substance for rational case interpretation. <i>Wiley Interdisciplinary Reviews Forensic Science</i> , 2018, , e1174.	2.1	5
28	Mass Spectrometry for Research and Application in Therapeutic Drug Monitoring or Clinical and Forensic Toxicology. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 389-393.	2.0	30
29	Nano liquid chromatography-high-resolution mass spectrometry for the identification of metabolites of the two new psychoactive substances N-(ortho-methoxybenzyl)-3,4-dimethoxyamphetamine and N-(ortho-methoxybenzyl)-4-methylmethamphetamine. <i>Talanta</i> , 2018, 188, 111-123.	5.5	17
30	Can toxicokinetics of (synthetic) cannabinoids in pigs after pulmonary administration be upscaled to humans by allometric techniques?. <i>Biochemical Pharmacology</i> , 2018, 155, 403-418.	4.4	9
31	Inhibition and stimulation of the human breast cancer resistance protein as in vitro predictor of drug-drug interactions of drugs of abuse. <i>Archives of Toxicology</i> , 2018, 92, 2875-2884.	4.2	11
32	Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives. <i>Drug Testing and Analysis</i> , 2017, 9, 115-126.	2.6	8
33	LC-HR-MS/MS standard urine screening approach: Pros and cons of automated on-line extraction by turbulent flow chromatography versus dilute-and-shoot and comparison with established urine precipitation. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1043, 138-149.	2.3	20
34	Metabolic patterns of JWH-210, RCS-4, and THC in pig urine elucidated using LC-HR-MS/MS: Do they reflect patterns in humans?. <i>Drug Testing and Analysis</i> , 2017, 9, 613-625.	2.6	10
35	Metabolic fate and detectability of the new psychoactive substances 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25B-NBOMe) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) in human and rat urine by GC-MS, LC-MS ⁿ , and LC-HR-MS/MS approaches. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 134, 158-169.	2.8	39
36	Dried urine spots - A novel sampling technique for comprehensive LC-MS ⁿ drug screening. <i>Analytica Chimica Acta</i> , 2017, 982, 112-121.	5.4	28

#	ARTICLE	IF	CITATIONS
37	Pooled human liver preparations, HepaRG, or HepG2 cell lines for metabolism studies of new psychoactive substances? A study using MDMA, MDD, butylone, MDP, MDPV, MDPB, 5-MAPB, and 5-API as examples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 143, 32-42.	2.8	55
38	Liquid chromatography-high resolution-tandem mass spectrometry using Orbitrap technology for comprehensive screening to detect drugs and their metabolites in blood plasma. <i>Analytica Chimica Acta</i> , 2017, 965, 83-95.	5.4	60
39	In vitro monoamine oxidase inhibition potential of alpha-methyltryptamine analog new psychoactive substances for assessing possible toxic risks. <i>Toxicology Letters</i> , 2017, 272, 84-93.	0.8	20
40	Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MSn, and LC-HR-MS/MS. <i>Analytical and Bioanalytical Chemistry</i> , 2017, 409, 1681-1695.	3.7	18
41	An easy and fast adenosine 5'-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5'-triphosphatase activity of the human breast cancer resistance protein ABCG2. <i>Journal of Chromatography A</i> , 2017, 1521, 123-130.	3.7	6
42	Paper Spray Ionization Coupled to High Resolution Tandem Mass Spectrometry for Comprehensive Urine Drug Testing in Comparison to Liquid Chromatography-Coupled Techniques after Urine Precipitation or Dried Urine Spot Workup. <i>Analytical Chemistry</i> , 2017, 89, 11779-11786.	6.5	51
43	New psychoactive substances: Studies on the metabolism of XLR-11, AB-PINACA, FUB-PB-22, 4-methoxy-1-PVP, 25-INBOMe, and meclonazepam using human liver preparations in comparison to primary human hepatocytes, and human urine. <i>Toxicology Letters</i> , 2017, 280, 142-150.	0.8	49
44	Post-modern Medicolegal and Forensic Toxicology. , 2017, , 450-457.		1
45	New Psychoactive Substances 3-Methoxyphencyclidine (3-MeO-PCP) and 3-Methoxyrolicyclidine (3-MeO-PCPy): Metabolic Fate Elucidated with Rat Urine and Human Liver Preparations and their Detectability in Urine by GC-MS, LC-(High Resolution)-MS and LC-(High Resolution)-MS/MS. <i>Current Neuropharmacology</i> , 2017, 15, 692-712.	2.9	27
46	Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and 9-Tetrahydrocannabinol After Intravenous Administration to Pigs. <i>Current Neuropharmacology</i> , 2017, 15, 713-723.	2.9	21
47	New Psychoactive Substances. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 4-11.	2.0	56
48	High-resolution mass spectrometry in toxicology: current status and future perspectives. <i>Archives of Toxicology</i> , 2016, 90, 2161-2172.	4.2	86
49	Metabolic fate of desomorphine elucidated using rat urine, pooled human liver preparations, and human hepatocyte cultures as well as its detectability using standard urine screening approaches. <i>Analytical and Bioanalytical Chemistry</i> , 2016, 408, 6283-6294.	3.7	34
50	Development and validation of a multi-analyte LC-MS/MS approach for quantification of neuroleptics in whole blood, plasma, and serum. <i>Drug Testing and Analysis</i> , 2016, 8, 1080-1089.	2.6	16
51	The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. <i>Journal of Hypertension</i> , 2016, 34, 2475-2479.	0.5	8
52	Pharmacokinetics of (synthetic) cannabinoids in pigs and their relevance for clinical and forensic toxicology. <i>Toxicology Letters</i> , 2016, 253, 7-16.	0.8	33
53	Review: LC coupled to low- and high-resolution mass spectrometry for new psychoactive substance screening in biological matrices "Where do we stand today?". <i>Analytica Chimica Acta</i> , 2016, 927, 13-20.	5.4	83
54	What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?. <i>Toxicology Letters</i> , 2016, 258, 55-70.	0.8	41

#	ARTICLE	IF	CITATIONS
55	Diphenidine, a new psychoactive substance: metabolic fate elucidated with rat urine and human liver preparations and detectability in urine using GC-MS, LC-MS ⁿ , and LC-HR-MS ⁿ . Drug Testing and Analysis, 2016, 8, 1005-1014.	2.6	15
56	Systematic forensic toxicological analysis by GC-MS in serum using automated mass spectral deconvolution and identification system. Drug Testing and Analysis, 2016, 8, 816-825.	2.6	21
57	In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Archives of Toxicology, 2016, 90, 305-318.	4.2	28
58	Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicology Letters, 2016, 241, 82-94.	0.8	20
59	Multiple stage MS in analysis of plasma, serum, urine and <i>in vitro</i> samples relevant to clinical and forensic toxicology. Bioanalysis, 2016, 8, 457-481.	1.5	13
60	In-vitro toxicokinetics of New Psychotropic Substances (NPS). Toxicology Letters, 2015, 238, S23.	0.8	0
61	Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance. Journal of Hypertension, 2015, 33, 2519-2525.	0.5	40
62	Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxy Piperamide (MeOP). Journal of Mass Spectrometry, 2015, 50, 1163-1174.	1.6	12
63	GC-MS, LC-MS ⁿ , LC-high resolution-MS ⁿ , and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high <i>“Kanna”</i> isolated from <i>Sceletium tortuosum</i> . Analytical and Bioanalytical Chemistry, 2015, 407, 761-778.	3.7	29
64	P-glycoprotein interactions of novel psychoactive substances <i>“Stimulation of ATP consumption and transport across Caco-2 monolayers.”</i> Biochemical Pharmacology, 2015, 94, 220-226.	4.4	27
65	Lefetamine, a controlled drug and pharmaceutical lead of new designer drugs: synthesis, metabolism, and detectability in urine and human liver preparations using GC-MS, LC-MS ⁿ , and LC-high resolution-MS/MS. Analytical and Bioanalytical Chemistry, 2015, 407, 1545-1557.	3.7	11
66	Metabolic fate, mass spectral fragmentation, detectability, and differentiation in urine of the benzofuran designer drugs 6-APB and 6-MAPB in comparison to their 5-isomers using GC-MS and LC-(HR)-MS ⁿ techniques. Analytical and Bioanalytical Chemistry, 2015, 407, 3457-3470.	3.7	23
67	Analytical characterization of bioactive <i>N</i> -benzyl-substituted phenethylamines and 5-methoxytryptamines. Rapid Communications in Mass Spectrometry, 2015, 29, 573-584.	1.5	16
68	Studies on the metabolism and toxicological detection of the new psychoactive designer drug 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe) in human and rat urine using GC-MS, LC-MS ⁿ , and LC-HR-MS/MS. Analytical and Bioanalytical Chemistry, 2015, 407, 6697-6719.	3.7	66
69	In situ antibiofilm effect of glass-ionomer cement containing dimethylaminododecyl methacrylate. Dental Materials, 2015, 31, 992-1002.	3.5	22
70	Simultaneous LC-MS/MS determination of JWH-210, RCS-4, Δ^9 -tetrahydrocannabinol, and their main metabolites in pig and human serum, whole blood, and urine for comparing pharmacokinetic data. Analytical and Bioanalytical Chemistry, 2015, 407, 3775-3786.	3.7	23
71	Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clinical Research in Cardiology, 2015, 104, 1097-1105.	3.3	76
72	Toxicokinetics of lefetamine and derived diphenylethylamine designer drugs <i>“Contribution of human cytochrome P450 isozymes to their main phase I metabolic steps.”</i> Toxicology Letters, 2015, 238, 39-44.	0.8	12

#	ARTICLE	IF	CITATIONS
73	Orbitrap technology for comprehensive metabolite-based liquid chromatographic high resolution-tandem mass spectrometric urine drug screening – Exemplified for cardiovascular drugs. <i>Analytica Chimica Acta</i> , 2015, 891, 221-233.	5.4	116
74	Metabolism of the new psychoactive substances N,N-diallyltryptamine (DALT) and 5-methoxy-DALT and their detectability in urine by GC-MS, LC-MS n, and LC-HR-MS-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 7831-7842.	3.7	41
75	A simple extraction and LC-MS/MS approach for the screening and identification of over 100 analytes in eight different matrices. <i>Drug Testing and Analysis</i> , 2015, 7, 214-240.	2.6	36
76	Benzofuran analogues of amphetamine and methamphetamine: studies on the metabolism and toxicological analysis of 5-APB and 5-MAPB in urine and plasma using GC-MS and LC-(HR)-MSn techniques. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 1371-1388.	3.7	61
77	Witnessed drug intake before planned denervation – Always harmless?. <i>International Journal of Cardiology</i> , 2015, 179, 125-126.	1.7	8
78	Contribution of human esterases to the metabolism of selected drugs of abuse. <i>Toxicology Letters</i> , 2015, 232, 159-166.	0.8	28
79	Elucidation of the metabolites of the novel psychoactive substance 4-methyl-N-ethylcathinone (4-MEC) in human urine and pooled liver microsomes by GC-MS and LC-HR-MS/MS techniques and of its detectability by GC-MS or LC-MS standard screening approaches. <i>Drug Testing and Analysis</i> , 2015, 7, 368-375.	2.6	43
80	Biotransformation and detectability of the designer drug 2,5-dimethoxy-4-propylphenethylamine (2C-P) studied in urine by GC-MS, LC-MS n, and LC-high-resolution-MS n. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 831-843.	3.7	13
81	Development and validation of a fast and simple multi-analyte procedure for quantification of 40 drugs relevant to emergency toxicology using GC-MS and one-point calibration. <i>Drug Testing and Analysis</i> , 2014, 6, 472-481.	2.6	24
82	Current position of high-resolution MS for drug quantification in clinical & forensic toxicology. <i>Bioanalysis</i> , 2014, 6, 2275-2284.	1.5	41
83	Forensic and clinical toxicology. <i>Bioanalysis</i> , 2014, 6, 2187-2187.	1.5	2
84	Application of a UHPLC MS/MS-Based Multianalyte Approach for Screening and Validated Quantification of Drugs in Human Blood Plasma Often Requested in the Context of Brain Death Diagnosis. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 257-260.	2.0	8
85	Direct analysis of the mushroom poisons Î±- and Î²-amanitin in human urine using a novel on-line turbulent flow chromatography mode coupled to liquid chromatography high resolution-mass spectrometry/mass spectrometry. <i>Journal of Chromatography A</i> , 2014, 1325, 92-98.	3.7	43
86	Behavioral and neurochemical characterization of kratom (<i>Mitragyna speciosa</i>) extract. <i>Psychopharmacology</i> , 2014, 231, 13-25.	3.1	47
87	Dimethocaine, a synthetic cocaine analogue: studies on its in-vivo metabolism and its detectability in urine by means of a rat model and liquid chromatography linear ion-trap (high-resolution) mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 1845-1854.	3.7	20
88	Detection and quantification of benzodiazepines and Z-drugs in human whole blood, plasma, and serum samples as part of a comprehensive multi-analyte LC-MS/MS approach. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 803-818.	3.7	34
89	Studies on the metabolism and the detectability of 4-methyl-amphetamine and its isomers 2-methyl-amphetamine and 3-methyl-amphetamine in rat urine using GC-MS and LC-(high-resolution)-MS n. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 1957-1974.	3.7	30
90	Can JWH-210 and JWH-122 be detected in adipose tissue four weeks after single oral drug administration to rats?. <i>Biomedical Chromatography</i> , 2014, 28, 1043-1047.	1.7	7

#	ARTICLE	IF	CITATIONS
91	A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 Î²-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 225-237.	3.7	34
92	The <i>in vivo</i> and <i>in vitro</i> metabolism and the detectability in urine of 3-(3,4-methylenedioxyphenyl)-1-pyrrolidinobutyrophenone (MDPBP), a new pyrrolidinophenone-type designer drug, studied by GC-MS and LC-MS. <i>Drug Testing and Analysis</i> , 2014, 6, 746-756.	3.7	23
93	Acute combined poisoning with the new designer drug 4-methyl-N-ethyl-cathinone (4-MEC) and gammabutyrolactone (GBL): A case report with different analytical approaches for identification of some metabolites. <i>Toxicologie Analytique Et Clinique</i> , 2014, 26, 119-127.	0.1	5
94	Lefetamine-derived designer drugs <i>N</i> -ethyl-1,2-diphenylethylamine (NEDPA) and <i>N</i> -isopropyl-1,2-diphenylethylamine (NPDPA): Metabolism and detectability in rat urine using GC-MS, LC-MS and LC-HR-MS/MS. <i>Drug Testing and Analysis</i> , 2014, 6, 1038-1048.	3.7	21
95	Development of an <i>in vitro</i> cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. <i>Toxicology Letters</i> , 2014, 230, 28-35.	0.8	37
96	Quantification of 33 antidepressants by LC-MS/MS comparative validation in whole blood, plasma, and serum. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 5939-5953.	3.7	30
97	GC-MS and LC-(high-resolution)-MS studies on the metabolic fate and detectability of amphetamine in rat urine. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 3815-3829.	3.7	10
98	Development and validation of a liquid-chromatography high-resolution tandem mass spectrometry approach for quantification of nine cytochrome P450 (CYP) model substrate metabolites in an <i>in vitro</i> CYP inhibition cocktail. <i>Analytical and Bioanalytical Chemistry</i> , 2014, 406, 4453-4464.	3.7	21
99	Methylenedioxy designer drugs: Mass spectrometric characterization of their glutathione conjugates by means of liquid chromatography-high-resolution mass spectrometry/mass spectrometry and studies on their glutathionyl transferase inhibition potency. <i>Analytica Chimica Acta</i> , 2014, 822, 37-50.	5.4	16
100	Dimethocaine, a synthetic cocaine derivative: Studies on its <i>in vitro</i> metabolism catalyzed by P450s and NAT2. <i>Toxicology Letters</i> , 2014, 225, 139-146.	0.8	11
101	Toxicokinetics of novel psychoactive substances: Characterization of N-acetyltransferase (NAT) isoenzymes involved in the phase II metabolism of 2C designer drugs. <i>Toxicology Letters</i> , 2014, 227, 124-128.	0.8	13
102	Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR)-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 6307-6321.	3.7	45
103	Studies on the <i>in vivo</i> contribution of human cytochrome P450s to the hepatic metabolism of glaucine, a new drug of abuse. <i>Biochemical Pharmacology</i> , 2013, 86, 1497-1506.	4.4	14
104	Studies on the metabolism and toxicological detection of glaucine, an isoquinoline alkaloid from <i>Glaucium flavum</i> (Papaveraceae), in rat urine using GC-MS, LC-MS and LC-high-resolution MS. <i>Journal of Mass Spectrometry</i> , 2013, 48, 24-41.	1.6	32
105	The <i>In Vivo</i> TRPV6 Protein Starts at a Non-AUG Triplet, Decoded as Methionine, Upstream of Canonical Initiation at AUG. <i>Journal of Biological Chemistry</i> , 2013, 288, 16629-16644.	3.4	63
106	Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. <i>Toxicology Letters</i> , 2013, 217, 137-142.	0.8	13
107	Qualitative metabolism assessment and toxicological detection of xylazine, a veterinary tranquilizer and drug of abuse, in rat and human urine using GC-MS, LC-MS, and LC-HR-MS. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 9779-9789.	3.7	24
108	What is the future of (ultra) high performance liquid chromatography coupled to low and high resolution mass spectrometry for toxicological drug screening?. <i>Journal of Chromatography A</i> , 2013, 1292, 19-24.	3.7	89

#	ARTICLE	IF	CITATIONS
109	2-Methiopropamine, a thiophene analogue of methamphetamine: studies on its metabolism and detectability in the rat and human using GC-MS and LC-(HR)-MS techniques. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 3125-3135.	3.7	67
110	Studies on the metabolism and detectability of the designer drug Î²-naphyrone in rat urine using GC-MS and LC-MS/MS. <i>Drug Testing and Analysis</i> , 2013, 5, 259-265.	2.6	20
111	Studies on the metabolism and detectability of the emerging drug of abuse diphenyl-2-pyrrolidinemethanol (D2PM) in rat urine using GC-MS and LC-MS/MS. <i>Journal of Mass Spectrometry</i> , 2013, 48, 243-249.	1.6	10
112	Coexpression of CPR from Various Origins Enhances Biotransformation Activity of Human CYPs in <i>S. pombe</i> . <i>Applied Biochemistry and Biotechnology</i> , 2013, 170, 1751-1766.	2.9	23
113	Case report of accidental poisoning with the tranquilizer xylazine and the anesthetic ketamine confirmed by qualitative and quantitative toxicological analysis using GC-MS and LC-MS. <i>Drug Testing and Analysis</i> , 2013, 5, 785-789.	2.6	18
114	How Can Analytical Diagnostics in Clinical Toxicology Be Successfully Performed Today?. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 561-564.	2.0	16
115	Chiral drug analysis using mass spectrometric detection relevant to research and practice in clinical and forensic toxicology. <i>Journal of Chromatography A</i> , 2012, 1269, 122-135.	3.7	58
116	Production and NMR analysis of the human ibuprofen metabolite 3-hydroxyibuprofen. <i>Journal of Biotechnology</i> , 2012, 157, 417-420.	3.8	26
117	Investigations on the stereoselectivity of the phase II metabolism of the 3,4-methylenedioxyethylamphetamine (MDEA) metabolites 3,4-dihydroxyethylamphetamine (DHEA) and 4-hydroxy-3-methoxyethylamphetamine (HMEA). <i>Toxicology Letters</i> , 2012, 212, 38-47.	0.8	4
118	Engineering of Human CYP3A Enzymes by Combination of Activating Polymorphic Variants. <i>Applied Biochemistry and Biotechnology</i> , 2012, 168, 785-796.	2.9	13
119	Biofilm inhibition by an experimental dental resin composite containing octenidine dihydrochloride. <i>Dental Materials</i> , 2012, 28, 974-984.	3.5	29
120	Current applications of high-resolution mass spectrometry in drug metabolism studies. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 1221-1231.	3.7	79
121	High-resolution mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 403, 1201-1202.	3.7	4
122	Objective assessment of nonadherence and unknown co-medication in hospitalized patients. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1191-1199.	1.9	9
123	Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans. <i>Biochemical Pharmacology</i> , 2012, 83, 131-138.	4.4	22
124	Towards a universal LC-MS screening procedure â€“ can an LIT LC-MS ⁿ screening approach and reference library be used on a quadrupole-LIT hybrid instrument?. <i>Journal of Mass Spectrometry</i> , 2012, 47, 66-71.	1.6	31
125	New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. <i>Journal of Mass Spectrometry</i> , 2012, 47, 253-262.	1.6	84
126	Current status of hyphenated mass spectrometry in studies of the metabolism of drugs of abuse, including doping agents. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 195-208.	3.7	36

#	ARTICLE	IF	CITATIONS
127	Qualitative studies on the metabolism and the toxicological detection of the fentanyl-derived designer drugs 3-methylfentanyl and isofentanyl in rats using liquid chromatography-linear ion trap-mass spectrometry (LC-MSn). <i>Analytical and Bioanalytical Chemistry</i> , 2012, 402, 1249-1255.	3.7	40
128	Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. <i>Pharmacogenomics</i> , 2011, 12, 215-233.	1.3	88
129	Sulfation of the 3,4-methylenedioxymethamphetamine (MDMA) metabolites 3,4-dihydroxymethamphetamine (DHMA) and 4-hydroxy-3-methoxymethamphetamine (HMMA) and their capability to inhibit human sulfotransferases. <i>Toxicology Letters</i> , 2011, 202, 120-128.	0.8	22
130	Development, Validation, and Application of a Fast and Simple GC-MS Method for Determination of Some Therapeutic Drugs Relevant in Emergency Toxicology. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 649-653.	2.0	19
131	Doxepin concentrations in plasma and cerebrospinal fluid. <i>Journal of Neural Transmission</i> , 2011, 118, 641-645.	2.8	7
132	Development of the first metabolite-based LC-MS n urine drug screening procedure-exemplified for antidepressants. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 79-88.	3.7	112
133	Monitoring of kratom or Krypton intake in urine using GC-MS in clinical and forensic toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 127-135.	3.7	47
134	Metabolism studies of the Kratom alkaloid speciociliatine, a diastereomer of the main alkaloid mitragynine, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 399, 2747-2753.	3.7	25
135	Forensic toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 7-8.	3.7	4
136	A validated GC-MS procedure for fast, simple, and cost-effective quantification of glycols and GHB in human plasma and their identification in urine and plasma developed for emergency toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 411-414.	3.7	52
137	Full validation and application of an ultra high performance liquid chromatographic-tandem mass spectrometric procedure for target screening and quantification of 34 antidepressants in human blood plasma as part of a comprehensive multi-analyte approach. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 2093-2107.	3.7	39
138	Drugs of abuse screening in urine as part of a metabolite-based LC-MSn screening concept. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 400, 3481-3489.	3.7	132
139	Ultra high performance liquid chromatographic-tandem mass spectrometric multi-analyte procedure for target screening and quantification in human blood plasma: validation and application for 31 neuroleptics, 28 benzodiazepines, and Z-drugs. <i>Analytical and Bioanalytical Chemistry</i> , 2011, 401, 1341-1352.	3.7	52
140	Convenient Gram-Scale Metabolite Synthesis by Engineered Fission Yeast Strains Expressing Functional Human P450 Systems. <i>Applied Biochemistry and Biotechnology</i> , 2011, 163, 965-980.	2.9	62
141	Intrahepatic Cholestasis Following Abuse of Powdered Kratom (<i>Mitragyna speciosa</i>). <i>Journal of Medical Toxicology</i> , 2011, 7, 227-231.	1.5	116
142	Development and validation of LC-HRMS and GC-NCI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine. <i>Journal of Mass Spectrometry</i> , 2011, 46, 603-614.	1.6	30
143	Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2011, 1814, 161-167.	2.3	21
144	Metabolism studies of the Kratom alkaloids mitraciliatine and isopayantheine, diastereomers of the main alkaloids mitragynine and paynantheine, in rat and human urine using liquid chromatography-linear ion trap-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 1049-1055.	2.3	31

#	ARTICLE	IF	CITATIONS
145	Investigation on the Enantioselectivity of the Sulfation of the Methylenedioxymethamphetamine Metabolites 3,4-Dihydroxymethamphetamine and 4-Hydroxy-3-Methoxymethamphetamine using the Substrate-Depletion Approach. <i>Drug Metabolism and Disposition</i> , 2011, 39, 1998-2002.	3.3	16
146	Urinary Excretion Kinetics of 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) and Its Phase I and Phase II Metabolites in Humans following Controlled MDMA Administration. <i>Clinical Chemistry</i> , 2011, 57, 1748-1756.	3.2	23
147	Sympathomimetic toxicity in a case of analytically confirmed recreational use of naphyrone (naphthylprovalerone). <i>Clinical Toxicology</i> , 2011, 49, 691-693.	1.9	45
148	Perspectives of Liquid Chromatography Coupled to Low- and High-Resolution Mass Spectrometry for Screening, Identification, and Quantification of Drugs in Clinical and Forensic Toxicology. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 324-327.	2.0	80
149	Chemistry, Pharmacology, and Metabolism of Emerging Drugs of Abuse. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 544-549.	2.0	66
150	Use of liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry for studying the metabolism of paynantheine, an alkaloid of the herbal drug Kratom in rat and human urine. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2379-2391.	3.7	44
151	Beta-keto amphetamines: studies on the metabolism of the designer drug mephedrone and toxicological detection of mephedrone, butylone, and methylene in urine using gas chromatography-mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 1225-1233.	3.7	246
152	Fast and simple procedure for liquid-liquid extraction of 136 analytes from different drug classes for development of a liquid chromatographic-tandem mass spectrometric quantification method in human blood plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 397, 2303-2314.	3.7	67
153	Phase I and II metabolites of speciogynine, a diastereomer of the main Kratom alkaloid mitragynine, identified in rat and human urine by liquid chromatography coupled to low- and high-resolution linear ion trap mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2010, 45, 1344-1357.	1.6	41
154	Studies on the metabolism of the pyrrolidinophenone designer drug methylenedioxypropylpyrrolidone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. <i>Journal of Mass Spectrometry</i> , 2010, 45, 1426-1442.	1.6	168
155	An automated screening method for drugs and toxic compounds in human serum and urine using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 2726-2732.	2.3	34
156	The breast feeding mother and xenon anaesthesia: four case reports. <i>Breast feeding and xenon anaesthesia. BMC Anesthesiology</i> , 2010, 10, 1.	1.8	23
157	Systematic investigation of ion suppression and enhancement effects of fourteen stable isotope-labeled internal standards by their native analogues using atmospheric-pressure chemical ionization and electrospray ionization and the relevance for multi-analyte liquid chromatographic/mass spectrometric procedures. <i>Rapid Communications in Mass Spectrometry</i> , 2010, 24, 2958-2967.	1.5	103
158	Ion suppression and enhancement effects of co-eluting analytes in multi-analyte approaches: systematic investigation using ultra-high-performance liquid chromatography/mass spectrometry with atmospheric-pressure chemical ionization or electrospray ionization. <i>Rapid Communications in Mass Spectrometry</i> , 2010, 24, 3103-3108.	1.5	127
159	Gas Chromatography-Mass Spectrometry Detection of a Norfluoxetine Artifact in Hydrolyzed Urine Samples May Falsely Indicate Tranylcypromine Ingestion. <i>Journal of Analytical Toxicology</i> , 2010, 34, 45-48.	2.8	5
160	Production of human phase 1 and 2 metabolites by whole-cell biotransformation with recombinant microbes. <i>Bioanalysis</i> , 2010, 2, 1277-1290.	1.5	41
161	Aus dem Blut ins LC-MS/MS. <i>Nachrichten Aus Der Chemie</i> , 2010, 58, 1268-1269.	0.0	0
162	CYP21-catalyzed production of the long-term urinary metandienone metabolite 17 β -hydroxymethyl-17 α -methyl-18-norandrost-1,4,13-trien-3-one: a contribution to the fight against doping. <i>Biological Chemistry</i> , 2010, 391, 119-27.	2.5	32

#	ARTICLE	IF	CITATIONS
163	Automated Mass Spectral Deconvolution and Identification System for GC-MS Screening for Drugs, Poisons, and Metabolites in Urine. <i>Clinical Chemistry</i> , 2010, 56, 575-584.	3.2	120
164	Analytical toxicology. <i>Exs</i> , 2010, 100, 317-338.	1.4	27
165	Metabolism of Designer Drugs of Abuse: An Updated Review. <i>Current Drug Metabolism</i> , 2010, 11, 468-482.	1.2	100
166	Biotechnological Synthesis of the Designer Drug Metabolite 4'-Hydroxymethyl- α -pyrrolidino-hexanophenone in Fission Yeast Heterologously Expressing Human Cytochrome P450 2D6--A Versatile Alternative to Multistep Chemical Synthesis. <i>Journal of Analytical Toxicology</i> , 2009, 33, 190-197.	2.8	25
167	The Role of Human UDP-Glucuronyltransferases on the Formation of the Methylenedioxyamphetamine (Ecstasy) Phase II Metabolites <i>R</i> - and <i>S</i> -3-Methoxymethamphetamine 4- <i>O</i> -Glucuronides. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2212-2220.	3.3	28
168	The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxyethylamphetamine and Its Single Enantiomers. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1152-1156.	3.3	23
169	Human CYP4Z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. <i>Biological Chemistry</i> , 2009, 390, 313-317.	2.5	49
170	Biotechnological synthesis of drug metabolites using human cytochrome P450 isozymes heterologously expressed in fission yeast. <i>Bioanalysis</i> , 2009, 1, 821-830.	1.5	15
171	Further Studies on the Role of Metabolites in (\pm)-3,4-Methylenedioxyamphetamine-Induced Serotonergic Neurotoxicity. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2079-2086.	3.3	51
172	Investigations on the cytochrome P450 (CYP) isoenzymes involved in the metabolism of the designer drugs N-(1-phenyl cyclohexyl)-2-ethoxyethanamine and N-(1-phenylcyclohexyl)-2-methoxyethanamine. <i>Biochemical Pharmacology</i> , 2009, 77, 444-450.	4.4	15
173	Stereoselective differences in the cytochrome P450-dependent dealkylation and demethylenation of N-methyl-benzodioxolyl-butanamine (MBDB, Eden) enantiomers. <i>Biochemical Pharmacology</i> , 2009, 77, 1725-1734.	4.4	25
174	New designer drug α -pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2009, 44, 952-964.	1.6	83
175	Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2009, 44, 1249-1261.	1.6	95
176	Studies on the metabolism of the Δ^9 -tetrahydrocannabinol precursor Δ^9 -tetrahydrocannabinolic acid A (Δ^9 -THCA) in rat using LC-MS/MS, LC-QTOF MS and GC-MS techniques. <i>Journal of Mass Spectrometry</i> , 2009, 44, 1423-1433.	2009	48
177	Use of fission yeast heterologously expressing human cytochrome P450 2B6 in biotechnological synthesis of the designer drug metabolite N-(1-phenylcyclohexyl)-2-hydroxyethanamine. <i>Forensic Science International</i> , 2009, 184, 69-73.	2.2	23
178	Mass spectrometric approaches in impaired driving toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 97-107.	3.7	57
179	Hydrolysis of 3,4-methylenedioxyamphetamine (MDMA) metabolite conjugates in human, squirrel monkey, and rat plasma. <i>Analytical and Bioanalytical Chemistry</i> , 2009, 393, 1607-1617.	3.7	13
180	Simultaneous liquid chromatographic-electrospray ionization mass spectrometric quantification of 3,4-methylenedioxyamphetamine (MDMA, Ecstasy) and its metabolites 3,4-dihydroxyamphetamine, 4-hydroxy-3-methoxymethamphetamine and 3,4-methylenedioxyamphetamine in squirrel monkey and human plasma after acidic conjugate cleavage. <i>Forensic Science International</i> , 2009, 184, 64-68.	2.2	15

#	ARTICLE	IF	CITATIONS
181	Analysis of toxic alkaloids in body samples. <i>Forensic Science International</i> , 2009, 185, 1-9.	2.2	89
182	Enantioselectivity in the Methylation of the Catecholic Phase I Metabolites of Methylenedioxy Designer Drugs and Their Capability To Inhibit Catechol-O-methyltransferase-Catalyzed Dopamine 3-Methylation. <i>Chemical Research in Toxicology</i> , 2009, 22, 1205-1211.	3.3	36
183	Investigations on the human hepatic cytochrome P450 isozymes involved in the metabolism of 3,4-methylenedioxy-amphetamine (MDA) and benzodioxolyl-butanamine (BDB) enantiomers. <i>Toxicology Letters</i> , 2009, 190, 54-60.	0.8	16
184	Direct Comparison of (±) 3,4-Methylenedioxymethamphetamine (â€œEcstasyâ€) Disposition and Metabolism in Squirrel Monkeys and Humans. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 367-373.	2.0	18
185	Metabolism and toxicological detection of the designer drug N-(1-phenylcyclohexyl)-3-methoxypropanamine (PCMPA) in rat urine using gas chromatographyâ€“mass spectrometry. <i>Forensic Science International</i> , 2008, 181, 47-51.	2.2	16
186	Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 390, 1837-1842.	3.7	36
187	New designer drugs <i>N</i>-1-phenylcyclohexyl)-2-ethoxyethanamine (PCEEA) and <i>N</i>-1-phenylcyclohexyl)-2-methoxyethanamine (PCMEA): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2008, 43, 305-316.	1.6	29
188	Designer drug 2,5-dimethoxy-4-methyl-amphetamine (DOM, STP): Involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatographyâ€“mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 862, 252-256.	2.3	17
189	Liquid chromatographicâ€“electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihoxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in rat brain. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 874, 110-124.	2.3	13
190	Metabolism and toxicological detection of a new designer drug, N-(1-phenylcyclohexyl)propanamine, in rat urine using gas chromatographyâ€“mass spectrometry. <i>Journal of Chromatography A</i> , 2008, 1186, 380-390.	3.7	20
191	Chapter 8 Non-opioid analgesics. <i>Handbook of Analytical Separations</i> , 2008, , 319-356.	0.8	1
192	2,5-Dimethoxyamphetamine-derived designer drugs: Studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. <i>Toxicology Letters</i> , 2008, 183, 52-57.	0.8	26
193	Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the Designer Drugs <i>N</i>-1-Phenylcyclohexyl)-3-ethoxypropanamine and <i>N</i>-1-Phenylcyclohexyl)-3-methoxypropanamine. <i>Chemical Research in Toxicology</i> , 2008, 21, 1949-1955.	3.3	13
194	Chapter 12 Forensic screening with GC-MS. <i>Handbook of Analytical Separations</i> , 2008, 6, 425-445.	0.8	4
195	Identification of Cytochrome P450 Enzymes Involved in the Metabolism of the New Designer Drug 4â€“Methyl-1-pyrrolidinobutyrophenone. <i>Drug Metabolism and Disposition</i> , 2008, 36, 163-168.	3.3	19
196	Nonlinear Pharmacokinetics of (±)3,4-Methylenedioxymethamphetamine (MDMA, â€œEcstasyâ€) and Its Major Metabolites in Squirrel Monkeys at Plasma Concentrations of MDMA That Develop After Typical Psychoactive Doses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 38-44.	2.5	31
197	Chapter 6 Sedatives and hypnotics. <i>Handbook of Analytical Separations</i> , 2008, 6, 243-286.	0.8	2
198	The Role of Human Hepatic Cytochrome P450 Isozymes in the Metabolism of Racemic 3,4-Methylenedioxy-Methamphetamine and Its Enantiomers. <i>Drug Metabolism and Disposition</i> , 2008, 36, 2345-2354.	3.3	88

#	ARTICLE	IF	CITATIONS
199	Doping Control Analysis of Methoxyphenamine Using Liquid Chromatography-Tandem Mass Spectrometry. <i>European Journal of Mass Spectrometry</i> , 2008, 14, 145-152.	1.0	11
200	Comparison of Urinary On-Site Immunoassay Screening and Gas Chromatography-Mass Spectrometry Results of 111 Patients With Suspected Poisoning Presenting at an Emergency Department. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 27-39.	2.0	31
201	Negative-Ion Chemical Ionization Gas Chromatography-Mass Spectrometry Assay for Enantioselective Measurement of Amphetamines in Oral Fluid: Application to a Controlled Study with MDMA and Driving Under the Influence Cases. <i>Clinical Chemistry</i> , 2007, 53, 702-710.	3.2	33
202	Systematic Comparison of Bias and Precision Data Obtained with Multiple-Point and One-Point Calibration in Six Validated Multianalyte Assays for Quantification of Drugs in Human Plasma. <i>Analytical Chemistry</i> , 2007, 79, 4967-4976.	6.5	46
203	Detection and validated quantification of nine herbal phenalkylamines and methcathinone in human blood plasma by LC-MS/MS with electrospray ionization. <i>Journal of Mass Spectrometry</i> , 2007, 42, 150-160.	1.6	77
204	Detection and validated quantification of toxic alkaloids in human blood plasma—comparison of LC-APCI-MS with LC-ESI-MS/MS. <i>Journal of Mass Spectrometry</i> , 2007, 42, 621-633.	1.6	89
205	Studies on the toxicological detection of the designer drug 4-bromo-2,5-dimethoxy- β -phenethylamine (2C-B) in rat urine using gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 846, 374-377.	2.3	34
206	Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 857, 170-174.	2.3	23
207	Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxyamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 855, 262-270.	2.3	21
208	Identification of monoamine oxidase and cytochrome P450 isoenzymes involved in the deamination of phenethylamine-derived designer drugs (2C-series). <i>Biochemical Pharmacology</i> , 2007, 73, 287-297.	4.4	50
209	Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4- α -hydroxymethyl- β -pyrrolidinobutyrophenone. <i>Biochemical Pharmacology</i> , 2007, 74, 511-520.	4.4	43
210	Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2007, 388, 1315-1325.	3.7	242
211	Analytical toxicology. <i>Analytical and Bioanalytical Chemistry</i> , 2007, 388, 1311-1311.	3.7	10
212	Demands on scientific studies in clinical toxicology. <i>Forensic Science International</i> , 2007, 165, 194-198.	2.2	25
213	Abuse of Nutmeg (<i>Myristica fragrans</i> Houtt.): Studies on the Metabolism and the Toxicologic Detection of its Ingredients Elemicin, Myristicin, and Safrole in Rat and Human Urine Using Gas Chromatography/Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 568-575.	2.0	90
214	Toxicokinetics of Drugs of Abuse: Current Knowledge of the Isoenzymes Involved in the Human Metabolism of Tetrahydrocannabinol, Cocaine, Heroin, Morphine, and Codeine. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 447-453.	2.0	132
215	Studies on the metabolism and toxicological detection of the designer drug 4-ethyl-2,5-dimethoxy- β -phenethylamine (2C-E) in rat urine using gas chromatographic-mass spectrometric techniques. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 842, 76-90.	2.3	36
216	Designer drugs 2,5-dimethoxy-4-bromo-amphetamine (DOB) and 2,5-dimethoxy-4-bromo-methamphetamine (MDOB): studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2006, 41, 487-498.	1.6	48

#	ARTICLE	IF	CITATIONS
217	New designer drug 4-iodo-2,5-dimethoxy- β -phenethylamine (2C-I): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric and capillary electrophoretic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2006, 41, 872-886.	1.6	48
218	New designer drug N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2006, 41, 1014-1029.	1.6	24
219	Designer drug 2,4,5-trimethoxyamphetamine (TMA-2): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2006, 41, 1140-1148.	1.6	23
220	Hyphenated mass spectrometric techniques are indispensable tools in clinical and forensic toxicology and in doping control. <i>Journal of Mass Spectrometry</i> , 2006, 41, 1399-1413.	1.6	103
221	Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl- β -phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques. <i>Journal of Mass Spectrometry</i> , 2006, 41, 1509-1519.	1.6	25
222	Very Low Ethanol Concentrations Affect the Viability and Growth Recovery in Post-Stationary-Phase <i>Staphylococcus aureus</i> Populations. <i>Applied and Environmental Microbiology</i> , 2006, 72, 2627-2636.	3.1	43
223	Screening Procedure for Detection of Stimulant Laxatives and/or Their Metabolites in Human Urine Using Gas Chromatography-Mass Spectrometry after Enzymatic Cleavage of Conjugates and Extractive Methylation. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 151-157.	2.0	23
224	Fast, Simple, and Validated Gas Chromatographic-Mass Spectrometric Assay for Quantification of Drugs Relevant to Diagnosis of Brain Death in Human Blood Plasma Samples. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 334-344.	2.0	37
225	Screening Procedure for Detection of Diuretics and Uricosurics and/or Their Metabolites in Human Urine Using Gas Chromatography-Mass Spectrometry After Extractive Methylation. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 509-520.	2.0	38
226	Toward High-Throughput Drug Screening Using Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 686-688.	2.0	38
227	Studies on the metabolism and toxicological detection of the new designer drug 4-methyl- β -pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 824, 81-91.	2.3	49
228	Studies on the metabolism and toxicological detection of the designer drug 4-methylthioamphetamine (4-MTA) in human urine using gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 824, 123-131.	2.3	43
229	Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology. <i>Clinical Biochemistry</i> , 2005, 38, 310-318.	1.9	173
230	New designer drug, 2,5-dimethoxy-4-propylthio- β -phenethylamine (2C-T-7): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 105-116.	1.6	70
231	Screening for and validated quantification of phenethylamine-type designer drugs and mescaline in human blood plasma by gas chromatography/mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 785-795.	1.6	58
232	New designer drug 2,5-dimethoxy-4-ethylthio- β -phenethylamine (2C-T-2): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2005, 40, 1157-1172.	1.6	54
233	Advances in analytical toxicology: the current role of liquid chromatography-mass spectrometry in drug quantification in blood and oral fluid. <i>Analytical and Bioanalytical Chemistry</i> , 2005, 381, 110-118.	3.7	134
234	Metabolism of Designer Drugs of Abuse. <i>Current Drug Metabolism</i> , 2005, 6, 259-274.	1.2	107

#	ARTICLE	IF	CITATIONS
235	Drug Testing in Blood: Validated Negative-Ion Chemical Ionization Gas Chromatographic-Mass Spectrometric Assay for Enantioselective Measurement of the Designer Drugs MDEA, MDMA, and MDA and Its Application to Samples from a Controlled Study with MDMA. <i>Clinical Chemistry</i> , 2005, 51, 1811-1822.	3.2	49
236	Screening par chromatographie liquide couplée à la spectrométrie de masse (LC-MS). <i>Toxicologie Analytique Et Clinique</i> , 2005, 17, 13-18.	0.1	6
237	IDENTIFICATION OF HUMAN CYTOCHROME P450 2D6 AS MAJOR ENZYME INVOLVED IN THEO-DEMETHYLATION OF THE DESIGNER DRUGP-METHOXYMETHAMPHETAMINE. <i>Drug Metabolism and Disposition</i> , 2004, 32, 379-381.	3.3	36
238	Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 1310-24.	2.3	153
239	Cytochrome P450 isoenzymes involved in rat liver microsomal metabolism of californine and protopine. <i>European Journal of Pharmacology</i> , 2004, 485, 69-79.	3.5	20
240	Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). <i>Biochemical Pharmacology</i> , 2004, 67, 235-244.	4.4	33
241	Fenproporex N-dealkylation to amphetamine enantioselective in vitro studies in human liver microsomes as well as enantioselective in vivo studies in Wistar and Dark Agouti rats. <i>Biochemical Pharmacology</i> , 2004, 68, 947-957.	4.4	14
242	High prevalence of unknown co-medication in hospitalised patients. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 363-8.	1.9	16
243	Environmental risk assessment of medicinal products for human use according to European Commission recommendations. <i>Environmental Toxicology</i> , 2004, 19, 226-240.	4.0	120
244	New designer drug 1-(3,4-methylenedioxybenzyl) piperazine(MDBP): studies on its metabolism and toxicological detection in rat urine using gas chromatography/mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2004, 39, 255-261.	1.6	44
245	Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. <i>Journal of Mass Spectrometry</i> , 2004, 39, 856-872.	1.6	139
246	Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 804, 337-343.	2.3	17
247	Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 127-131.	2.0	130
248	Studies on the Human Metabolism and the Toxicologic Detection of the Cough Suppressant Dropropizine in Urine Using Gas Chromatography-Mass Spectrometry. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 441-449.	2.0	16
249	Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization. <i>Journal of Chromatography A</i> , 2004, 1058, 169-81.	3.7	16
250	Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. <i>Journal of Mass Spectrometry</i> , 2003, 38, 283-295.	1.6	125
251	Screening for and validated quantification of amphetamines and of amphetamine- and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2003, 38, 659-676.	1.6	162
252	New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. <i>Journal of Mass Spectrometry</i> , 2003, 38, 971-981.	1.6	65

#	ARTICLE	IF	CITATIONS
253	Metabolism of the new designer drug \pm -pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4 \pm -methyl \pm -pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 796, 253-266.	2.3	77
254	Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 798, 333-342.	2.3	38
255	New designer drug 4 \pm -methyl \pm -pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789, 79-91.	2.3	57
256	Studies on the metabolism and toxicological detection of the Eschscholtzia californica alkaloids californine and protopine in urine using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789, 43-57.	2.3	31
257	New designer drug p-methoxymethamphetamine: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 789, 27-41.	2.3	50
258	Metabolism and toxicological detection of the new designer drug 4 \pm -methoxy \pm -pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 793, 331-342.	2.3	56
259	Metabolism and toxicological detection of the new designer drug 3 \pm ,4 \pm -methylenedioxy \pm -pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 793, 377-388.	2.3	57
260	Amphetamine Concentrations in Human Urine following Single-Dose Administration of the Calcium Antagonist Prenylamine-Studies Using Fluorescence Polarization Immunoassay (FPIA) and GC-MS. Journal of Analytical Toxicology, 2003, 27, 68-73.	2.8	22
261	IDENTIFICATION OF CYTOCHROME P450 ENZYMES INVOLVED IN THE METABOLISM OF 4 \pm -METHYL \pm -PYRROLIDINOPROPIOPHENONE, A NOVEL SCHEDULED DESIGNER DRUG, IN HUMAN LIVER MICROSOMES. Drug Metabolism and Disposition, 2003, 31, 979-982.	3.3	29
262	Concentrations and Ratios of Amphetamine, Methamphetamine, MDA, MDMA, and MDEA Enantiomers Determined in Plasma Samples from Clinical Toxicology and Driving Under the Influence of Drugs Cases by GC-NICI-MS*. Journal of Analytical Toxicology, 2003, 27, 552-559.	2.8	65
263	Piperazine-Derived Designer Drug 1-(3-Chlorophenyl)piperazine (mCPP): GC-MS Studies on its Metabolism and its Toxicological Detection in Rat Urine Including Analytical Differentiation from its Precursor Drugs Trazodone and Nefazodone*. Journal of Analytical Toxicology, 2003, 27, 560-568.	2.8	49
264	Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives. Therapeutic Drug Monitoring, 2002, 24, 277-289.	2.0	199
265	Role of Gas Chromatography-Mass Spectrometry With Negative Ion Chemical Ionization in Clinical and Forensic Toxicology, Doping Control, and Biomonitoring. Therapeutic Drug Monitoring, 2002, 24, 247-254.	2.0	60
266	Negative Ion Chemical Ionization Gas Chromatography-Mass Spectrometry and Atmospheric Pressure Chemical Ionization Liquid Chromatography-Mass Spectrometry of Low-Dosed and/or Polar Drugs in Plasma. Therapeutic Drug Monitoring, 2002, 24, 117-124.	2.0	42
267	Bioanalytical method validation and its implications for forensic and clinical toxicology - A review. , 2002, , 1-9.		21
268	Validated assay for quantification of oxcarbazepine and its active dihydro metabolite 10-hydroxycarbazepine in plasma by atmospheric pressure chemical ionization liquid chromatography/mass spectrometry. Journal of Mass Spectrometry, 2002, 37, 687-692.	1.6	43
269	Bioanalytical method validation and its implications for forensic and clinical toxicology - A review. Accreditation and Quality Assurance, 2002, 7, 441-449.	0.8	198
270	Screening, library-assisted identification and validated quantification of oral antidiabetics of the sulfonylurea-type in plasma by atmospheric pressure chemical ionization liquid chromatography-mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 773, 63-73.	2.3	91

#	ARTICLE	IF	CITATIONS
271	Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 773, 35-46.	2.3	93
272	Studies on the metabolism and toxicological detection of the new designer drug 4-methyl-1-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 773, 25-33.	2.3	54
273	Drug Testing in Blood: Validated Negative-Ion Chemical Ionization Gas Chromatographic-Mass Spectrometric Assay for Determination of Amphetamine and Methamphetamine Enantiomers and Its Application to Toxicology Cases. <i>Clinical Chemistry</i> , 2002, 48, 1472-1485.	3.2	72
274	Drug testing in blood: validated negative-ion chemical ionization gas chromatographic-mass spectrometric assay for determination of amphetamine and methamphetamine enantiomers and its application to toxicology cases. <i>Clinical Chemistry</i> , 2002, 48, 1472-85.	3.2	17
275	Screening Procedure for Detection of Non-Steroidal Anti-inflammatory Drugs and their Metabolites in Urine as Part of a Systematic Toxicological Analysis Procedure for Acidic Drugs and Poisons by Gas Chromatography- Mass Spectrometry after Extractive Methylation*. <i>Journal of Analytical Toxicology</i> , 2001, 25, 237-244.	2.8	76
276	Screening for Detection of New Antidepressants, Neuroleptics, Hypnotics, and Their Metabolites in Urine by GC-MS Developed Using Rat Liver Microsomes. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 61-70.	2.0	76
277	Validated gas chromatographic-mass spectrometric assay for determination of the antifreezes ethylene glycol and diethylene glycol in human plasma after microwave-assisted pivalylation. <i>Biomedical Applications</i> , 2001, 754, 401-409.	1.7	34
278	The Antispasmodic Drug Mebeverine Leads to Positive Amphetamine Results by Fluorescence Polarization Immunoassay (FPIA)-Studies on the Toxicological Analysis of Urine by FPIA and GC-MS*. <i>Journal of Analytical Toxicology</i> , 2001, 25, 333-338.	2.8	30
279	Chapter 8 Non-opioid analgesics. <i>Handbook of Analytical Separations</i> , 2000, 2, 259-285.	0.8	0
280	Chromatographische Verfahren in der Toxikologie. <i>Nachrichten Aus Der Chemie</i> , 2000, 48, 390-391.	0.0	0
281	Gas chromatographic-mass spectrometric procedures for determination of the catechol-O-methyltransferase (COMT) activity and for detection of unstable catecholic metabolites in human and rat liver preparations after COMT catalyzed in statu nascendi derivatization using S-adenosylmethionine. <i>Biomedical Applications</i> , 2000, 739, 325-335.	1.7	19
282	Validated electrospray liquid chromatographic-mass spectrometric assay for the determination of the mushroom toxins $\hat{1}$ - and $\hat{2}$ -amanitin in urine after immunoaffinity extraction. <i>Biomedical Applications</i> , 2000, 748, 125-135.	1.7	84
283	Studies on the metabolism and toxicological detection of the amphetamine-like anorectic fenproporex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. <i>Biomedical Applications</i> , 2000, 738, 107-118.	1.7	32
284	Screening Procedures for Simultaneous Detection of Several Drug Classes Used for High Throughput Toxicological Analyses and Doping Control. A Review. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2000, 3, 467-480.	1.1	73
285	Chapter 6 Sedatives and hypnotics. <i>Handbook of Analytical Separations</i> , 2000, 2, 197-227.	0.8	2
286	Screening Procedure for Detection of Antidepressants of the Selective Serotonin Reuptake Inhibitor Type and their Metabolites in Urine as Part of a Modified Systematic Toxicological Analysis Procedure using Gas Chromatography-Mass Spectrometry*. <i>Journal of Analytical Toxicology</i> , 2000, 24, 340-347.	2.8	69
287	Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ($\hat{1}$ -Ecstasy $\hat{1}$ ™). <i>Toxicology Letters</i> , 2000, 112-113, 133-142.	0.8	162
288	Efficient Cleavage of Conjugates of Drugs or Poisons by Immobilized $\hat{2}$ -Glucuronidase and Arylsulfatase in Columns. <i>Clinical Chemistry</i> , 1999, 45, 2173-2182.	3.2	16

#	ARTICLE	IF	CITATIONS
289	Systematic toxicological analysis procedures for acidic drugs and/or metabolites relevant to clinical and forensic toxicology and/or doping control. Biomedical Applications, 1999, 733, 3-25.	1.7	95
290	Screening Procedure for Detection of Dihydropyridine Calcium Channel Blocker Metabolites in Urine as Part of a Systematic Toxicological Analysis Procedure for Acidic Compounds by Gas Chromatography-Mass Spectrometry after Extractive Methylation*. Journal of Analytical Toxicology, 1999, 23, 73-80.	2.8	50
291	Liquid chromatography-mass spectrometry in forensic and clinical toxicology. Biomedical Applications, 1998, 713, 3-25.	1.7	207
292	Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine. Biomedical Applications, 1998, 713, 163-187.	1.7	162
293	Detection of 4-hydroxycoumarin anticoagulants and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation. Biomedical Applications, 1998, 714, 181-195.	1.7	44
294	Screening for the Detection of Angiotensin-Converting Enzyme Inhibitors, Their Metabolites, and AT II Receptor Antagonists. Therapeutic Drug Monitoring, 1998, 20, 706-713.	2.0	61
295	Gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) in toxicological analysis Studies on the detection of clobenzorex and its metabolites within a systematic toxicological analysis procedure by GC-MS and by immunoassay and studies on the detection of 1±- and 1²-amanitin in urine by atmospheric pressure ionization electrospray LC-MS. Biomedical Applications, 1997, 689, 91-99.	1.7	61
296	Studies on the metabolism and toxicological detection of the amphetamine-like anorectic mefenorex in human urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. Biomedical Applications, 1997, 702, 93-102.	1.7	23
297	Analytical Development for Low Molecular Weight Xenobiotic Compounds1. Archives of Toxicology Supplement, 1997, 19, 189-197.	0.7	23
298	146 RAT LIVER MICROSOMES - AN EFFICIENT TOOL FOR DEVELOPING GC-MS PROCEDURES FOR DETECTION OF NEW DRUGS OR POISONS IN URINE. Therapeutic Drug Monitoring, 1997, 19, 583.	2.0	6
299	Toxicological detection of the designer drug 3,4-methylenedioxyethylamphetamine (MDE, "Eve") and its metabolites in urine by gas chromatography-mass spectrometry and fluorescence polarization immunoassay. Biomedical Applications, 1996, 683, 189-197.	1.7	70
300	On the Metabolism and the Toxicological Analysis of Methylenedioxyphenylalkylamine Designer Drugs by Gas Chromatography-Mass Spectrometry. Therapeutic Drug Monitoring, 1996, 18, 465-470.	2.0	104
301	Toxicological Analysis of Drugs: GC-MS Screening and Confirmation. , 1995, , 489-492.		5
302	Cyclic Ureas, III: On the Metabolism of the Enantiomers of Cyclic Ureas in Rats. Archiv Der Pharmazie, 1993, 326, 535-538.	4.1	0
303	Systematic toxicological analysis of drugs and their metabolites by gas chromatography-mass spectrometry. Biomedical Applications, 1992, 580, 3-41.	1.7	210
304	Toxicological detection of selegiline and its metabolites in urine using fluorescence polarization immunoassay (FPIA) and gas chromatography-mass spectrometry (GC-MS) and differentiation by enantioselective GC-MS of the intake of selegiline from abuse of methamphetamine or amphetamine. Archives of Toxicology, 1992, 66, 675-678.	4.2	91
305	Identification and differentiation of barbiturates, other sedative-hypnotics and their metabolites in urine integrated in a general screening procedure using computerized gas chromatography-mass spectrometry. Biomedical Applications, 1990, 530, 307-326.	1.7	36
306	Detection of anticonvulsants and their metabolites in urine within a "general unknown" analysis procedure using computerized gas chromatography-mass spectrometry. Archives of Toxicology, 1990, 64, 554-561.	4.2	19

#	ARTICLE	IF	CITATIONS
307	Identification of antiarrhythmic drugs and their metabolites in urine. Archives of Toxicology, 1990, 64, 218-230.	4.2	21
308	Toxicological detection of pholcodine and its metabolites in urine and hair using radio immunoassay, fluorescence polarisation immunoassay, enzyme immunoassay and gas chromatography-mass spectrometry. International Journal of Legal Medicine, 1990, 104, 43-46.	2.2	32
309	Chromatography of histamine H1- and H2-receptor blockers in biosamples. Biomedical Applications, 1990, 531, 369-405.	1.7	12
310	Identification and differentiation of alkylamine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. Biomedical Applications, 1988, 430, 31-41.	1.7	32
311	Identification and quantification of ethylene glycol and diethylene glycol in plasma using gas chromatography-mass spectrometry. Archives of Toxicology, 1988, 62, 66-69.	4.2	27
312	Identification of phenothiazine antihistamines and their metabolites in urine. Archives of Toxicology, 1988, 62, 185-191.	4.2	26
313	Screening procedure for the detection of alkanolamine antihistamines and their metabolites in urine using computerized gas chromatography-mass spectrometry. Biomedical Applications, 1988, 428, 43-60.	1.7	25
314	Toxicological detection of ethylenediamine and piperazine antihistamines and their metabolites in urine by computerized gas chromatography-mass spectrometry. Fresenius Zeitschrift für Analytische Chemie, 1988, 331, 744-756.	0.8	17
315	Toxicological detection of ajmaline, prajmaline and their metabolites in urine integrated in a "general-unknown" analysis procedure using gas chromatography-mass spectrometry. Fresenius Zeitschrift für Analytische Chemie, 1988, 330, 459-460.	0.8	5
316	Identification and differentiation of benzodiazepines and their metabolites in urine by computerized gas chromatography-mass spectrometry. Biomedical Applications, 1987, 422, 85-101.	1.7	88
317	Identification and differentiation of beta-blockers and their metabolites in urine by computerized gas chromatography-mass spectrometry. Biomedical Applications, 1986, 382, 147-165.	1.7	53
318	Screening procedure for the detection of antiparkinsonian drugs and their metabolites in urine using a computerized gas chromatographic-mass spectrometric technique. Fresenius Zeitschrift für Analytische Chemie, 1985, 321, 363-370.	0.8	14
319	Screening procedure for detection of phenothiazine and analogous neuroleptics and their metabolites in urine using a computerized gas chromatographic-mass spectrometric technique. Biomedical Applications, 1984, 306, 125-145.	1.7	41
320	Screening procedure for detection of antidepressants and their metabolites in urine using a computerized gas chromatographic-mass spectrometric technique. Biomedical Applications, 1984, 305, 309-323.	1.7	29
321	Screening procedure for detecting butyrophenone and bisfluorophenyl neuroleptics in urine using a computerized gas chromatographic-mass spectrometric technique. Biomedical Applications, 1983, 272, 75-85.	1.7	30
322	Determination of 1,4- and 1,5-benzodiazepines in urine using a computerized gas chromatographic-mass spectrometric technique. Biomedical Applications, 1981, 222, 409-419.	1.7	45